The average Wall Street analyst following Editas Medicine ( EDIT 7.08%) thinks the gene therapy stock can reach $3.25 per ...

Fintel reports that on June 27, 2025, Clear Street downgraded their outlook for CRISPR Therapeutics (NasdaqGM:CRSP) from Buy ...

Vor Bio is licensing global rights a fusion protein that inhibits two targets to potentially treat the neuromuscular disorder ...

According to Benzinga Pro, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.62%, which means the company has less short interest than most of its peers. Did ...